Direxion Daily S&P Biotech Bear 3X ETF (LABD) Covered Calls

Direxion Daily S&P Biotech Bear 3X Shares is an exchange-traded fund that seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund creates short exposure to the biotechnology sector through the use of swap agreements, futures contracts, and other financial instruments. It is designed as a short-term trading vehicle for investors betting on a decline in biotech stock prices.

You can sell covered calls on Direxion Daily S&P Biotech Bear 3X ETF to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for LABD (prices last updated Fri 1:30 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

The Direxion Daily S&P Biotech Bear 3X Shares (LABD) is a leveraged inverse exchange-traded fund managed by Rafferty Asset Management. Unlike traditional stocks, LABD is a financial product designed to profit from the decline of an underlying index—specifically the S&P Biotechnology Select Industry Index. The fund utilizes derivatives such as total return swaps and futures contracts to achieve its daily objective of triple inverse exposure.

Because the fund rebalances its exposure every day, it is intended primarily for short-term tactical use by sophisticated traders. The fund’s performance is tied to a diversified basket of biotechnology companies ranging from small-cap innovators to large-cap pharmaceutical giants. By providing a way to hedge against sector-wide downturns or speculate on bearish trends, LABD serves as a specialized tool within the healthcare segment of the capital markets.

Competitive Landscape

The market for leveraged and inverse ETFs is highly specialized, with a few key players providing the majority of these high-velocity trading instruments. LABD competes directly with other products that track the same or similar biotechnology and healthcare indices. Key competitors and related products include:

1. Direxion Daily S&P Biotech Bull 3X Shares: The direct counterpart to LABD, offering 300% leveraged long exposure to the same biotechnology index.
2. SPDR S&P Biotech ETF: The primary non-leveraged fund that tracks the underlying index upon which LABD bases its inverse performance.
3. Direxion Daily Healthcare Bull 3X Shares: A leveraged fund providing bullish exposure to the broader healthcare sector, often used by the same class of traders.
4. iShares Biotechnology ETF: A major unleveraged competitor that tracks a different, market-cap-weighted biotechnology index.
5. ProShares UltraPro Short Nasdaq Biotechnology: An inverse leveraged fund tracking a similar sector, though it does not trade on the NYSE or NASDAQ exchanges.

Strategic Outlook and Innovation

The strategy for LABD is strictly dictated by its mandate to provide daily inverse leverage. As a result, its "innovation" lies in the efficiency of its swap agreements and its ability to minimize tracking error relative to its 300% inverse goal. The fund remains a cornerstone for traders looking to navigate high volatility within the biotechnology industry, which is frequently impacted by regulatory shifts and clinical trial outcomes.

The fund management focuses on maintaining liquidity to ensure that institutional and retail traders can enter and exit large positions with minimal slippage. By optimizing its collateral holdings, which typically consist of short-term government securities and cash, the fund aims to maintain a stable operational structure. This allows it to function effectively as an evergreen instrument for those seeking to capitalize on downward momentum in one of the market’s most volatile sectors.

Want more examples? LAB Covered Calls | LABU Covered Calls